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ABSTRACT
Objectives: In some countries, nicotine-containing
electronic cigarettes (e-cigarettes) are considered a
consumer product without specific regulations. In
others (eg, Switzerland), the sale of e-cigarettes
containing nicotine is forbidden, despite the eagerness
of many smokers to obtain them. As scientific data
about efficacy and long-term safety of these products
are scarce, tobacco control experts are divided on how
to regulate them. In order to gain consensus among
experts to provide recommendations to health
authorities, we performed a national consensus study.
Setting: We used a Delphi method with electronic
questionnaires to bring together the opinion of Swiss
experts on e-cigarettes.
Participants: 40 Swiss experts from across the
country.
Outcome measures: We measured the degree of
consensus between experts on recommendations
regarding regulation, sale, use of and general opinion
about e-cigarettes containing nicotine. New
recommendations and statements were added
following the experts’ answers and comments.
Results: There was consensus that e-cigarettes
containing nicotine should be made available, but only
under specific conditions. Sale should be restricted to
adults, using quality standards, a maximum level of
nicotine and with an accompanying list of authorised
ingredients. Advertisement should be restricted and
use in public places should be forbidden.
Conclusions: These recommendations encompass
three principles: (1) the reality principle, as the product
is already on the market; (2) the prevention principle,
as e-cigarettes provide an alternative to tobacco for
actual smokers, and (3) the precautionary principle, to
protect minors and non-smokers, since long-term
effects are not yet known. Swiss authorities should
design specific regulations to sell nicotine-containing
e-cigarettes.
INTRODUCTION
The use of electronic cigarettes (e-cigarettes)
has rapidly increased in recent years, raising
worldwide public debate. E-cigarettes include
a wide range of devices using aerosol delivery
methods and many unanswered questions
remain. The immediate effects after short-
term use of e-cigarettes have been described,1 2
but there are currently no data about the long-
term effects of their use; few studies have inves-
tigated the efﬁcacy of e-cigarettes in smoking
cessation or reduction.
In Switzerland, currently only e-cigarettes
without nicotine may be sold. Citizens can
buy e-liquids containing nicotine from
abroad or online, albeit a limited volume
and for personal use only.3 In Europe, the
current legislation varies from country to
country. A revision of the European directive
on tobacco products was adopted by the
European Parliament and this came into
force in May 2014. The member states have
2 years to adopt the new directive.
Some experts who consider the sale of
e-cigarettes as a possible revolution in harm
reduction from tobacco,4 therefore, advocate
that the use of these products should be
encouraged and not severely regulated, in
order to convince as many smokers as possible
to switch to e-cigarettes. Other experts argue
Strengths and limitations of this study
▪ There is need for health and political authorities to
be advised on how to regulate e-cigarettes contain-
ing nicotine. As data about long-term safety and
health impact of electronic cigarettes (e-cigarettes)
are scarce, an expert consensus is an appropriate
means to provide recommendations.
▪ These recommendations can be applied to other
countries that do not currently possess specific
regulations about nicotine-containing e-cigarettes.
▪ To the best of our knowledge, this study is the
first to use a formal consensus method to
propose expert opinion on such a regulation.
▪ The main limitation of the study is linked to the
Delphi method itself, as the results only reflect
the opinion of selected experts.
▪ Another limitation is linked to the rapid evolution
of the products and the continuous arrival of
new data on safety. Opinions in this report will
certainly change as more data become available.
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that e-cigarettes could provide a gateway to nicotine
dependence, especially for the young, leading to eventual
cigarette smoking. Their use would delay smoking cessa-
tion and would renormalise public smoking.5 These
hypotheses, however, have not been properly tested to
date and alternative smoking cessation aids already exist.6
Regulation of the sale of e-cigarettes containing nico-
tine will have a major effect on the development of the
product and therefore, on the health of the smoking
population. Given the current paucity of scientiﬁc evi-
dence to guide health and political authorities, a con-
sensus process is an appropriate way to determine what
tobacco control experts agree upon.
The aim of our study was to collect expert recommen-
dations for health authorities regarding the regulation,
sale and use of e-cigarettes containing nicotine.
METHODS
Procedure
We used the Delphi method to collect experts’ opinions.
The Delphi method7–9 is a validated consensus process,
frequently used when evidence is missing. An expert
panel is ﬁrst asked to rate the recommendations. The
experts are then provided the results of this ﬁrst round,
allowing them to rerate the recommendations for or
against a given consensus. This process can be repeated
to help the experts to reach a ﬁnal consensus.
In the present study, an online questionnaire was sub-
mitted to a panel of Swiss experts over the course of
four rounds, between September 2013 and January 2014
(ﬁgure 1), assessing the extent of their agreement on
different statements. The questions were adapted based
on the results and comments from the previous round.
The research team keeps the original questionnaires,
which were available for consultation. As no patient was
involved in the study, the Ethics Review Board from the
University of Lausanne conﬁrmed that as per the Swiss
legislation, no formal ethics approval was necessary.
Expert panel
The invited experts (n=113) came from several comple-
mentary expert networks: (1) The national programme
‘Vivre sans tabac’/‘Frei von Tabak’ (‘Free from
Tobacco’), including 50 physicians from all across
Switzerland trained to teach other physicians on how to
treat tobacco dependence,10 (2) the Swiss network
‘Hospital Quit Support’, a programme intended to bring
smoking cessation through consultations in Swiss hospi-
tals, (3) the Swiss university public health network and
(4) additional Swiss experts known to the research team
for their involvement in tobacco prevention from a clin-
ical or political perspective, as well as those recom-
mended by other experts participating in the study.
Round 1
The ﬁrst questionnaire addressed regulations, sale and
use of e-cigarettes. Participants had to rate each
recommendation on a scale of 1–10, where 1 was
‘strongly disagree’ and 10 was ‘strongly agree’. The
recommendations that reached a high level of positive
agreement (mean score between 8 and 10) were consid-
ered as accepted. The recommendations that reached a
high level of negative agreement (mean score between 1
and 3) were considered as rejected. The ﬁrst question-
naire also involved one open-ended question and the
possibility to suggest new recommendations. At the same
time, participants received documents about e-cigarettes
containing nicotine that included three national reports
(from UK,11 France12 and Germany13), as well as some
representative scientiﬁc and political information on the
topic.3 4 6 14–18
Example of a recommendation proposed in the ﬁrst
questionnaire:
2.1. Restrictions on sale of nicotine-containing e-cigarettes
should be proposed for:
▸ Non-smokers
▸ Pregnant women
▸ Minors
Round 2
The recommendations that did not reach a signiﬁcant
level of agreement (mean scores between 3.01 and 7.99)
were used to create the second questionnaire. They were
reformulated following the comments of the experts,
Figure 1 Flow chart of the participation of experts.
2 Blaser J, et al. BMJ Open 2015;5:e007197. doi:10.1136/bmjopen-2014-007197
Open Access
either to clarify the recommendation or to submit subcat-
egories. We used the answers to the open question, and
the experts’ suggestions and comments to create new
recommendations. In order to facilitate interpretation of
results, the experts were asked to rank some of the recom-
mendations in order from most appropriate to least appro-
priate. The degree of agreement was then determined by
the proportion of ﬁrst choice for each proposition.
Cut-offs were set to keep the same intervals used in the
other recommendations. The results of the ﬁrst round
from the second questionnaire were made anonymous
and provided once again to the experts. The comments
and results of the open questions were not transmitted. As
for the ﬁrst round, the recommendations that reached a
high level of positive or negative agreement were consid-
ered as accepted or rejected, respectively.
Rounds 3 and 4
The participants had access to the results of previous
rounds to rate the recommendations. This process was
repeated two more times, in order to reach a consensus
for as many recommendations as possible. For the last
round, we attached six recent position papers to the
questionnaire in order to present further arguments to
the participants.19–24
RESULTS
A total of 113 experts were invited to participate in the
study (ﬁgure 1). Of these, 46 accepted the invite to par-
ticipate in the ﬁrst round and 40 ﬁlled out the ﬁrst ques-
tionnaire. Only these 40 experts, who replied to the ﬁrst
round, were sent the next questionnaire. The participa-
tion rates for rounds 2, 3 and 4 were 97.5%, 97.5% and
95%, respectively.
Of the 40 experts who participated to the ﬁrst round,
80% (n=32) were Swiss experts in tobacco control, 12%
(n=5) were members of the Federal Commission for
Tobacco Control, and 8% (n=3) were proposed by other
experts. Thirty-ﬁve (62.5%) worked mainly as healthcare
practitioners (with patients who smoke) and 15 (37.5%)
were educators training other health professionals.
Twenty-two of the experts (55%) worked in the French
part of Switzerland, 16 (40%) in the German part and
two (5%) in the Italian part. Twenty-six (65%) were
males and 14 (35%) were females.
Box 1 shows the recommendations on the regulation
of e-cigarettes that reached a high level of agreement by
the end of the survey.
Box 2 summarises the recommendations on the sale
of e-cigarettes that reached a high level of agreement.
Box 3 shows the recommendations that reached a
high level of agreement on the use of e-cigarettes, as
well as their general opinion about the product.
DISCUSSION
The Swiss expert panel agreed that nicotine-containing
e-cigarettes should be sold under several restrictions and
without waiting for additional epidemiological or clinical
data. The potential of e-cigarettes to be a much safer
alternative to conventional cigarettes was the main argu-
ment for making them available as soon as possible.
Nevertheless, much consideration was given to the lack
of data about long-term effects of e-cigarettes on the
health of users. Therefore, they agreed on the need for
regulations that would protect users by guaranteeing the
quality of available e-cigarette products, with an upper
limit of authorised nicotine concentration, and adequate
information on the ingredients of the e-liquids and their
Box 1 Regulation
Item
▸ Nicotine-containing electronic cigarettes (e-cigarettes) should
be sold in Switzerland under specific regulation, different than
the current regulations
▸ E-cigarettes should be considered as either:
– A drug (medication), regulated by Swissmedic
– A new category of products containing nicotine, under spe-
cific regulation
▸ E-cigarettes should not be considered as:
– A tobacco product, regulated like other products containing
tobacco (such as cigarettes, pipes and cigars)
– A consumer product, without changing the actual regulation
▸ If e-cigarettes with nicotine were to be authorised in
Switzerland, companies should:
– Respect a list of authorised e-liquid ingredients
– Be on a list of accepted models with specific requirements
– Respect an upper limit of nicotine concentration
▸ A warning should be stated on the product, especially con-
cerning the potential for addiction and the lack of evidence
concerning long-term safety.
▸ The ingredients of the e-liquid should be stipulated on the
product.
Box 2 Sale
Item
▸ Restrictions on sales should be proposed for minors
▸ If electronic cigarettes (e-cigarettes) were considered as a
medication, restrictions should be proposed for minors and
pregnant women
▸ If nicotine-containing e-cigarettes were to be authorised in
Switzerland, they should not be sold by the tobacco industry
or related companies
▸ E-cigarettes should be sold in either:
– Pharmacies
– The same places as tobacco products
▸ E-cigarettes should not be sold:
– In specialised shops
– Anywhere
▸ A specific tax should be implemented on e-cigarettes
▸ Advertisement should not be allowed:
– In the media
– Targeting minors
– Targeting non-smokers
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addictive potential. A restrictive list for authorised ingre-
dients of e-liquids should be enacted. In order to
control quality and access to the products, nicotine-
containing e-cigarettes should be either considered as a
medication or regulated as a new category of products
containing nicotine through the enactment of a speciﬁc
regulation. The ﬁrst option would require time, as more
studies would be required before certain e-cigarettes
could be sold as a medical device. A speciﬁc regulation,
however, could include recommendations proposed by
the experts regarding the quality, safety, use and sale of
e-cigarettes.
In the present study, the beneﬁt of nicotine-containing
e-cigarettes for current tobacco cigarette smokers was
largely accepted, although the lack of data on long-term
health effects was taken into account. It seemed import-
ant to the experts, therefore, to protect minors and
current non-smokers by restricting sales of e-cigarettes to
adults, as well as by forbidding advertisements in the
media, especially those targeting minors and non-
smokers. Consideration was also given to the protection
of pregnant women, as we know that nicotine can have
negative effects on the fetus.25 In order to enforce the
proposed recommendations for regulation, e-cigarettes
should be sold either in pharmacies or in the same loca-
tions as tobacco products. The experts agreed that a tax
on e-cigarettes should be implemented, high enough to
ﬁnance independent research on e-cigarettes, but low
enough to keep the product more attractive than con-
ventional cigarettes.
Given the risk of renormalisation of smoking, as well
as the currently unknown effects of passive vaping, the
experts recommended that e-cigarettes should be
banned from closed public places. Health authorities
should recommend that non-smokers do not begin the
use of e-cigarettes, as the long-term effects on health are
not known. As evidence for the efﬁcacy of e-cigarettes as
a quitting tool is lacking, they also considered that
health professionals should not recommend e-cigarettes
as a ﬁrst-line treatment for quitting smoking conven-
tional cigarettes, but should instead recommend the use
of products (nicotine substitutes) and therapies that
already have proven efﬁcacy.
Given current data, the experts considered that
nicotine-containing e-cigarettes should not be perceived
as dangerous to the health of current smokers, as these
do have a potential for risk reduction for those who
switch from conventional cigarettes. On a societal level,
even if e-cigarettes seem to be a much safer way to
deliver nicotine than conventional cigarettes, experts
agreed that nicotine addiction should be considered as
a medical and public health issue, given its addictive
potential and unknown long-term effects on health, and
not as a moral issue.
Comparing these results to the current legislations in
Europe (see online supplementary appendix A), the
recommendations of the present study follow the trend
to allow e-cigarettes with nicotine. None of the neigh-
bouring countries, however, have speciﬁc regulations as
proposed in this study to date. The European directive
offers a few restrictions that are yet to be applied by the
member states, but which does not address many of the
concerns identiﬁed by the experts of this study.
The main limitation of the study is linked to the Delphi
method itself, as the results only reﬂect the opinion of
selected experts. Another limitation is linked to the rapid
evolution of the products and the continuous arrival of
new data about safety. Opinions in this report will cer-
tainly change as more data become available.
CONCLUSION
This study allowed a panel of experts to reach a consen-
sus on several important questions regarding e-cigarettes
containing nicotine, speciﬁcally their regulation, sale
and use. The study also gathered the general opinion of
experts on the nature of e-cigarettes. This should prove
useful for health authorities and healthcare profes-
sionals for future decision-making on the topic.
These recommendations encompass three principles:
the reality principle, as the product is already on the
market; the prevention principle, as they provide an alter-
native to tobacco for actual smokers; and the precaution-
ary principle, as they protect minors and non-smokers
while long-term effects remain largely unknown.
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Box 3 Use and general opinion
Item
▸ The use of electronic cigarettes (e-cigarettes) should be for-
bidden in public places
▸ Health authorities should advise never-smokers not to use
e-cigarettes (eg, through a public campaign)
▸ Health authorities should not encourage smokers to shift to
e-cigarettes to help them quit smoking as first-line therapy.
▸ If e-cigarettes were considered as a medication, they should
be either:
– Supplied with a prescription from a doctor
– Supplied on technical advice from medical staff (eg,
pharmacies)
▸ If e-cigarettes become a popular product, nicotine addiction
should be seen as a medical and a public health issue
▸ Research should assess:
– Long-term safety of the product
– Efficacy as a quitting tool
– Psychological and social effects
– Effect of dual consumption: e-cigarettes and tobacco
products
▸ Based on currently available data, e-cigarettes are not danger-
ous to the health of tobacco smokers
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